David Baanstra

5.5k total citations · 4 hit papers
9 papers, 3.9k citations indexed

About

David Baanstra is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, David Baanstra has authored 9 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 4 papers in Internal Medicine and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in David Baanstra's work include Atrial Fibrillation Management and Outcomes (5 papers), Venous Thromboembolism Diagnosis and Management (4 papers) and Diabetes Treatment and Management (4 papers). David Baanstra is often cited by papers focused on Atrial Fibrillation Management and Outcomes (5 papers), Venous Thromboembolism Diagnosis and Management (4 papers) and Diabetes Treatment and Management (4 papers). David Baanstra collaborates with scholars based in United States, Germany and Canada. David Baanstra's co-authors include Ajay K. Kakkar, Sam Schulman, Samuel Z. Goldhaber, Clive Kearon, Henry Eriksson, Sebastian Schellong, Patrick Mismetti, Janet Schnee, Jeffrey Friedman and Darren K. McGuire and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

David Baanstra

9 papers receiving 3.9k citations

Hit Papers

Dabigatran versus Warfarin in the Treatment of Acute Veno... 2009 2026 2014 2020 2009 2018 2013 2019 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
    2009 1.9k citations Sam Schulman, Clive Kearon et al. New England Journal of Medicine profile →
  2. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
    2018 756 citations Julio Rosenstock, Vlado Perkovic et al. JAMA profile →
  3. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
    2013 713 citations Sam Schulman, Clive Kearon et al. New England Journal of Medicine profile →
  4. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
    2019 394 citations Julio Rosenstock, Steven E. Kahn et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Baanstra United States 8 2.5k 2.3k 1.2k 828 437 9 3.9k
Urszula Masiukiewicz United States 14 1.9k 0.8× 1.5k 0.6× 2.0k 1.7× 1.1k 1.3× 225 0.5× 21 4.2k
Janet Schnee United States 21 4.8k 1.9× 4.0k 1.7× 666 0.6× 1.1k 1.4× 606 1.4× 45 6.1k
Farzin Beygui France 32 4.0k 1.6× 924 0.4× 855 0.7× 2.2k 2.7× 268 0.6× 155 5.2k
Rainer B. Zotz Germany 24 1.5k 0.6× 1.5k 0.6× 192 0.2× 626 0.8× 1.1k 2.4× 78 3.3k
Karine Lacut France 26 1.4k 0.6× 1.4k 0.6× 358 0.3× 659 0.8× 532 1.2× 119 2.8k
Melina Verso Italy 27 1.6k 0.7× 2.5k 1.1× 252 0.2× 711 0.9× 398 0.9× 59 3.6k
Anita Vedel Christiansen Germany 8 1.4k 0.5× 1.4k 0.6× 318 0.3× 419 0.5× 200 0.5× 13 1.8k
Jean‐Philippe Collet France 36 3.9k 1.6× 987 0.4× 717 0.6× 2.2k 2.6× 416 1.0× 124 5.1k
David J. Moliterno United States 39 5.7k 2.3× 1.3k 0.5× 270 0.2× 3.1k 3.7× 384 0.9× 100 6.6k
Timothy Brighton Australia 23 1.8k 0.7× 2.2k 0.9× 82 0.1× 732 0.9× 1.1k 2.5× 58 3.4k

Countries citing papers authored by David Baanstra

Since Specialization
Citations

This map shows the geographic impact of David Baanstra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Baanstra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Baanstra more than expected).

Fields of papers citing papers by David Baanstra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Baanstra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Baanstra. The network helps show where David Baanstra may publish in the future.

Co-authorship network of co-authors of David Baanstra

This figure shows the co-authorship network connecting the top 25 collaborators of David Baanstra. A scholar is included among the top collaborators of David Baanstra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Baanstra. David Baanstra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
McGuire, Darren K., John H. Alexander, Odd Erik Johansen, et al.. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 139(3). 351–361. 112 indexed citations
2.
Rosenstock, Julio, Steven E. Kahn, Odd Erik Johansen, et al.. (2019). Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. JAMA. 322(12). 1155–1155. 394 indexed citations breakdown →
3.
4.
Rosenstock, Julio, Vlado Perkovic, Odd Erik Johansen, et al.. (2018). Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA. 321(1). 69–69. 756 indexed citations breakdown →
5.
Schulman, Sam, Clive Kearon, Ajay K. Kakkar, et al.. (2013). Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. New England Journal of Medicine. 368(8). 709–718. 713 indexed citations breakdown →
6.
Schulman, Sam, Clive Kearon, Ajay K. Kakkar, et al.. (2013). Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. Survey of Anesthesiology. 57(5). 264–265. 21 indexed citations
7.
Schulman, Sam, David Baanstra, Henry Eriksson, et al.. (2012). Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up. Blood. 120(21). 21–21. 24 indexed citations
8.
Schulman, Sam, Clive Kearon, Ajay K. Kakkar, et al.. (2009). Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine. 361(24). 2342–2352. 1866 indexed citations breakdown →
9.
Schulman, Sam, Henry Eriksson, Samuel Z. Goldhaber, et al.. (2009). Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.. Blood. 114(22). 1–1. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Urszula Masiukiewicz Breakdown of academic impact, for papers by Janet Schnee Breakdown of academic impact, for papers by Farzin Beygui Breakdown of academic impact, for papers by Rainer B. Zotz Breakdown of academic impact, for papers by Karine Lacut Breakdown of academic impact, for papers by Melina Verso Breakdown of academic impact, for papers by Anita Vedel Christiansen Breakdown of academic impact, for papers by Jean‐Philippe Collet Breakdown of academic impact, for papers by David J. Moliterno Breakdown of academic impact, for papers by Timothy Brighton
Rankless by CCL
2026